Cargando…
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
BACKGROUND: Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. Standard therapy for heart failure (HF) is recommended for CTRCD, but there is n...
Autores principales: | Gregorietti, Vanesa, Fernandez, Teresa Lopez, Costa, Diego, Chahla, Elías Ortega, Daniele, Andrés J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643279/ https://www.ncbi.nlm.nih.gov/pubmed/33292750 http://dx.doi.org/10.1186/s40959-020-00078-4 |
Ejemplares similares
-
Cardio-Oncology in Argentina: Past, Present, and Future
por: Daniele, Andrés J., et al.
Publicado: (2020) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Sacubitril/Valsartan Shows Improvement of the Cardio-Ankle Vascular Index in a Hypertensive Patient
por: Shimizu, Kazuhiro, et al.
Publicado: (2023)